Human pharmacokinetics of 1-[2-[2-(4 pyridyl)-2-imidazolinyl-(1)]-ethyl]-3-(4-carboxyphenyl) urea (CGP 15720A)期刊界 All Journals 搜尽天下杂志传播学术成果专业期刊搜索期刊信息化学术搜索

Human pharmacokinetics of 1-[2-[2-(4 pyridyl)-2-imidazolinyl-(1)]-ethyl]-3-(4-carboxyphenyl) urea (CGP 15720A)

Authors:	L. Pendyala Ph.D. S. Madajewicz P. J. Creaven

Affiliation:	(1) Department of Clinical Pharmacology and Therapeutics, Roswell Park Memorial Institute, New York State Department of Health, 666 Elm Street, 14263 Buffalo, New York, USA;(2) Dept. Clinical Pharmacology and Therapeutics, Roswell Park Memorial Institute, 666 Elm Street, 14263 Buffalo, New York, USA

Abstract:	Summary Pharmacokinetics of CGP 15720A have been studied in patients receiving this drug in a short I.V. infusion during its phase I clinical trial. Plasma decay was biphasic with a mean t_1/2 of 4.9 ± 2.47h. The drug was cleared rapidly from plasma (7.02 ± 5.95 L/h). Renal clearance (4.13 ± 1.65 L/h) appears to be the major clearance pathway. The steady state volumes of distribution of the drug indicate limited tissue distribution for the drug. Studies with plasma and urine of patients receiving ¹⁴[C] GCP 15720A indicate that the drug is not metabolized. CGP 15720A could be measured in cerebrospinal fluid.

Keywords:	CGP 15720A pharmacokinetics
本文献已被 SpringerLink 等数据库收录！